Looking For Top Marijuana Stocks To Add To Your Portfolio? Here’s 3 To Watch In November
Marijuana stocks have seen a surge in overall interest this week. For example, Aphria Inc (APHA Stock Report) saw an impressive 19% increase in its share prices in the past few days. Companies who are not direct producers have also seen growth. This can be seen in marijuana real estate company Innovative Industrial‘s (IIPR Stock Report) sudden growth of 20% this week. To address the elephant in the room (or donkey in this case), this is likely due to the current standings of the U.S. presidential race.
The Biden/Harris candidacy has not been shy about their opinions on the calming substance. This in conjunction with their current lead in the polls could bring interesting opportunities for eagle-eyed investors. They have expressed strong views in favor of marijuana legalization. Considering this, investors could be flocking towards the marijuana industry. With Harris pledging decriminalization of the substance, it appears that investors anticipate a possible Biden/Harris win.
In addition to this, voters in three states approved ballot measures involving marijuana. They voted in favor of recreational marijuana in Arizona, New Jersey, and South Dakota. The results from Montana’s recreational ballot question and Mississippi’s medical measure have yet to be tallied. Although these initiatives are only the first steps in the process of legalization, marijuana companies are already riding this socio-political tailwind this week. Having said all this, here is a list of marijuana stocks that investors are watching.
Read More
- 3 Top Cloud Computing Stocks To Watch In November 2020
- Are These The Best Cybersecurity Stocks To Have In This Digital Age?
Top Marijuana Stocks To Watch In Q4 2020: Aurora Cannabis Inc
The first stock on this list is Aurora Cannabis Inc (ACB Stock Report). Aurora is a Canadian licensed cannabis producer that is headquartered in Edmonton. The company has eight licensed production facilities, five sales licenses, and operates in 25 countries. It also has a robust portfolio of medical and consumer brands under the company name.
In Q4 2020, the company produced over 44,000 kilograms of cannabis. This is a 23% increase from Q3 2020. As a result, Aurora saw higher overhead absorption, greater weighted average yields per plant, and capacity utilization. Ultimately, this contributed to a decrease in cash cost quarter-over-quarter. The company’s share price saw a phenomenal rise of 31% this week as well.
The company acquired private cannabidiol (CBD) company Reliva in May. Reliva is a big player in the U.S. CBD industry where its products are sold in over 20,000 retail locations across the country. With the company being the second largest in the market, this is undoubtedly a good move on Aurora’s part. This acquisition is likely Aurora’s means of penetrating the U.S. cannabis market. Consequently, investors are likely watching the company as it appears to have been preparing for a Biden/Harris win this year.
For the most part, Aurora has been making moves in anticipation of federal-level legalization of marijuana. With its extended reach into the U.S. market, high-tech low-cost production facilities, and science-driven innovations, could it be a top marijuana stock to watch?
Top Marijuana Stocks To Watch In Q4 2020: Canopy Growth Corp
The next stock on this list is Canopy Growth Corp (CGC Stock Report). Canopy is known as the largest cannabis company in the world based on market capitalization. The company is based in Ontario and was founded in 2013. In addition to its operation in Canada, Canopy also has partnership agreements with Spanish pharma company Alcaliber. The collaboration with Alcaliber serves as the company’s means of penetrating key European markets. It aims to do so by establishing European based cultivation and extraction capabilities. This essentially enables Alcaliber to grow and cultivate marijuana at its facilities for global sales.
In the last week, the company saw its shares jump 12% on Thursday’s intraday trading. Its fiscal Q1 2021 financials revealed a 22% increase in net revenue year-over-year. This in addition to a 50% improvement in free cash flow year-over-year may indicate that the company is recovering from its rough year in the stock market. Why is the company seeing this much movement?
Canopy is undoubtedly having a very busy week. The marijuana industry titan is in the limelight due to the current presidential race standings. However, another key piece of news would be its transition to Nasdaq’s (NDAQ Stock Report) Global Select Market. Its shares will reportedly start trading on the new exchange on November 16.
The company mentioned that this move is cheaper for the company compared to being listed on the New York Stock Exchange. CEO David Klein elaborated on this by saying that the move provided the company with “greater cost-effectiveness and access to a suite of tools and services that will help us connect more efficiently with our current and future investors.” With all things considered, will CGC stocks be a top marijuana stock to buy for the long run?
[Read More] Top Tech Stocks To Watch For Exposure To Bitcoin
Top Marijuana Stocks To Watch In Q4 2020: Tilray Inc
The final spot on this list goes to Tilray Inc (TLRY Stock Report). This Canadian pharmaceutical and cannabis company (founded in 2013) is based in Nanaimo. It also has operations in Australia, New Zealand, Germany, Portugal, and Latin America. Over the last few years, Tilray has made a string of strategic partnerships and acquisitions. As a result, the company’s portfolio now consists of a diverse collection of cannabis-based products.
This ranges from non-combustible medical products to non-alcoholic CBD-infused beverages and edibles. The most notable of these would be its acquisition of Manitoba Harvest which markets its CBD products in 13,000 stores all over the U.S. Tilray also ventures into the medical aspect of the industry via clinical trial testing of medical cannabis.
The company’s stock has seen an explosive growth of 30% on Thursday. In fiscal Q2 2020, it reported a 10% increase in year-over-year revenue with a 32% improvement of adjusted EBITDA year-over-year. This seemingly healthy growth could be a good sign for the company considering the challenging year it has had. With its Q3 financials set to be reported on November 9, investors are likely watching Tilray closely.
Assuming the votes go in favor of the marijuana industry, the company is undeniably looking for an entry point into the lucrative U.S. cannabis market. Tilray could have a means of doing so via its recent venture in medical cannabis clinical research. In September, the company published preliminary results regarding one of the company’s Good Manufacturing Practice (GMP) products. The results indicate that the product could be a promising means of reducing nausea and vomiting for cancer patients undergoing chemotherapy. With these findings and the current political landscape, TLRY stocks have earned its spot on this list.
